Biological Age And Outcomes In PCI

Overview

About this study

The purpose of this study is to evaluate the contribution of clinical deficits, functional impairment, epigenetic biomarkers, and proteomic profiles to the estimation of biological age in patients undergoing PCI.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients ≥65 years of age undergoing PCI.

Exclusion Criteria:

  • Prior stroke with significant residual neurological deficit; advanced dementia; severe Parkinson’s disease; life expectancy <1 year due to non-cardiac illness; or active substance abuse (drug/alcohol dependence).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/14/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mandeep Singh, M.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions